Prostate Cancer
News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.
News | Prostate Cancer | December 19, 2017
December 19, 2017 — Humanetics Corp. presented data at the annual meetings of the American Society for Radiation...
News | Treatment Planning | November 14, 2017
November 14, 2017 — Spectronic Medical announced that new data for their MRIPlanner software, generating synthetic...
News | Proton Therapy | October 30, 2017
October 30, 2017 — The National Association for Proton Therapy (NAPT) announced a number of clinical papers showing...
News | Molecular Imaging | October 26, 2017
October 26, 2017 — The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer...
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-...
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
October 10, 2017 — Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer...
News | Prostate Cancer | October 04, 2017
October 4, 2017 — Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an...
News | Prostate Cancer | October 03, 2017
October 3, 2017 — A new study finds that immune response in prostate cancer may be able to forecast how patients will...
News | Patient Positioning Radiation Therapy | September 22, 2017
September 22, 2017 — Augmenix Inc. announced a preview of clinical data that will be presented at the 59th Annual...
News | Proton Therapy | September 20, 2017
September 20, 2017 — ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free...
The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY
News | Prostate Cancer | September 14, 2017
September 14, 2017 — Researchers have demonstrated a new, effective way to precisely identify and localize prostate...
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALCON...
News | Patient Positioning Radiation Therapy | September 08, 2017
September 8, 2017 — Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U....
News | Patient Positioning Radiation Therapy | September 05, 2017
September 5, 2017 — Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC)...
Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.
News | Radiopharmaceuticals and Tracers | August 16, 2017
August 16, 2017 — In the featured translational article in the August issue of The Journal of Nuclear Medicine,...
News | Biopsy Systems | July 17, 2017
July 17, 2017 — Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical...
News | Patient Positioning Radiation Therapy | June 28, 2017
June 28, 2017 — Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR hydrogel...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney
News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.
Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.
This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.
Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.
News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017
News | Prostate Cancer | May 24, 2017
May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...
